Integrative radiation systems biology.

Kristian Unger
Author Information
  1. Kristian Unger: Research Unit Radiation Cytogenetics, Helmholtz-Zentrum München, German Research Center for Environmental Health, Ingolstädter-Landstr, 1, 85764 Neuherberg, Germany. unger@helmholtz-muenchen.de.

Abstract

Maximisation of the ratio of normal tissue preservation and tumour cell reduction is the main concept of radiotherapy alone or combined with chemo-, immuno- or biologically targeted therapy. The foremost parameter influencing this ratio is radiation sensitivity and its modulation towards a more efficient killing of tumour cells and a better preservation of normal tissue at the same time is the overall aim of modern therapy schemas. Nevertheless, this requires a deep understanding of the molecular mechanisms of radiation sensitivity in order to identify its key players as potential therapeutic targets. Moreover, the success of conventional approaches that tried to statistically associate altered radiation sensitivity with any molecular phenotype such as gene expression proofed to be somewhat limited since the number of clinically used targets is rather sparse. However, currently a paradigm shift is taking place from pure frequentistic association analysis to the rather holistic systems biology approach that seeks to mathematically model the system to be investigated and to allow the prediction of an altered phenotype as the function of one single or a signature of biomarkers. Integrative systems biology also considers the data from different molecular levels such as the genome, transcriptome or proteome in order to partially or fully comprehend the causal chain of molecular mechanisms. An example for the application of this concept currently carried out at the Clinical Cooperation Group "Personalized Radiotherapy in Head and Neck Cancer" of the Helmholtz-Zentrum München and the LMU Munich is described. This review article strives for providing a compact overview on the state of the art of systems biology, its actual challenges, potential applications, chances and limitations in radiation oncology research working towards improved personalised therapy concepts using this relatively new methodology.

References

  1. J Comput Biol. 2002;9(1):67-103 [PMID: 11911796]
  2. Nucleic Acids Res. 2010 Jul;38(Web Server issue):W275-80 [PMID: 20511592]
  3. Radiat Oncol. 2012 Nov 07;7:187 [PMID: 23134732]
  4. BMC Bioinformatics. 2012 May 04;13:80 [PMID: 22559006]
  5. Front Physiol. 2013 Oct 10;4:278 [PMID: 24133454]
  6. Nat Rev Genet. 2004 Jul;5(7):522-31 [PMID: 15211354]
  7. Radiat Environ Biophys. 2014 Mar;53(1):1-29 [PMID: 24141602]
  8. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41 [PMID: 21059682]
  9. Nat Rev Mol Cell Biol. 2008 Oct;9(10):770-80 [PMID: 18797474]
  10. Biosystems. 2006 Feb-Mar;83(2-3):81-90 [PMID: 16426740]
  11. Radiat Oncol. 2012 Jun 19;7:93 [PMID: 22713587]
  12. Nat Rev Genet. 2005 Aug;6(8):597-610 [PMID: 16136652]
  13. Radiat Oncol. 2009 Jun 04;4:17 [PMID: 19497124]
  14. Biochem J. 1913 Oct;7(5):471-80 [PMID: 16742267]
  15. Trends Biotechnol. 2008 Feb;26(2):70-6 [PMID: 18191262]
  16. Chromosome Res. 2005;13(3):237-48 [PMID: 15868418]
  17. Radiat Oncol. 2011 May 24;6:54 [PMID: 21609453]
  18. Adv Cancer Res. 2012;115:221-63 [PMID: 23021246]
  19. Trends Microbiol. 2007 Jan;15(1):45-50 [PMID: 17113776]
  20. Nature. 1970 Aug 8;227(5258):561-3 [PMID: 4913914]
  21. Nat Protoc. 2007;2(10):2366-82 [PMID: 17947979]
  22. Nat Cell Biol. 2001 Aug;3(8):E190-5 [PMID: 11483980]
  23. Trends Genet. 1994 Aug;10(8):286-92 [PMID: 7940758]
  24. Nature. 2012 Jan 26;483(7387):100-3 [PMID: 22281684]
  25. Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14 [PMID: 22080510]
  26. Radiat Oncol. 2011 Nov 10;6:153 [PMID: 22074483]
  27. Semin Radiat Oncol. 2012 Apr;22(2):108-18 [PMID: 22385918]
  28. Pharmacopsychiatry. 2013 May;46 Suppl 1:S10-21 [PMID: 23599240]
  29. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 [PMID: 21296855]
  30. PLoS Genet. 2012;8(10):e1003005 [PMID: 23093944]
  31. PLoS Comput Biol. 2013;9(9):e1003168 [PMID: 24039558]
  32. Brain Connect. 2011;1(4):295-308 [PMID: 22432419]
  33. Lancet Oncol. 2012 Jan;13(1):65-77 [PMID: 22169268]
  34. Cancer Cell. 2002 Sep;2(3):179-82 [PMID: 12242150]
  35. Mol Syst Biol. 2013;9:673 [PMID: 23752269]
  36. Nat Rev Genet. 2012 Sep;13(9):613-26 [PMID: 22868264]
  37. PLoS Genet. 2013;9(9):e1003803 [PMID: 24068968]
  38. Genomics. 2004 Mar;83(3):349-60 [PMID: 14986705]
  39. Radiat Oncol. 2012 Mar 20;7:39 [PMID: 22429326]
  40. Curr Protoc Cell Biol. 2004 Sep;Chapter 17:Unit 17.7 [PMID: 18228445]
  41. PLoS Comput Biol. 2012;8(2):e1002375 [PMID: 22383865]
  42. Nat Methods. 2012 Jul 15;9(8):796-804 [PMID: 22796662]
  43. J Endocrinol. 2009 Apr;201(1):1-13 [PMID: 19136617]
  44. Nucleic Acids Res. 2009 Jul;37(13):4181-93 [PMID: 19570852]
  45. BMC Syst Biol. 2011 Jan 31;5:21 [PMID: 21281499]
  46. Nucleic Acids Res. 2009 Jan;37(Database issue):D619-22 [PMID: 18981052]
  47. Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6 [PMID: 18940858]
  48. BMC Neurosci. 2006 Oct 30;7 Suppl 1:S10 [PMID: 17118154]

MeSH Term

Combined Modality Therapy
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Head and Neck Neoplasms
Humans
Organ Sparing Treatments
Quality Improvement
Radiation Tolerance
Radiotherapy
Systems Biology
Systems Integration

Word Cloud

Created with Highcharts 10.0.0radiationmolecularsystemsbiologytherapysensitivityrationormaltissuepreservationtumourconcepttowardsmechanismsorderpotentialtargetsalteredphenotyperathercurrentlyIntegrativeMaximisationcellreductionmainradiotherapyalonecombinedchemo-immuno-biologicallytargetedforemostparameterinfluencingmodulationefficientkillingcellsbettertimeoverallaimmodernschemasNeverthelessrequiresdeepunderstandingidentifykeyplayerstherapeuticMoreoversuccessconventionalapproachestriedstatisticallyassociategeneexpressionproofedsomewhatlimitedsincenumberclinicallyusedsparseHoweverparadigmshifttakingplacepurefrequentisticassociationanalysisholisticapproachseeksmathematicallymodelsysteminvestigatedallowpredictionfunctiononesinglesignaturebiomarkersalsoconsidersdatadifferentlevelsgenometranscriptomeproteomepartiallyfullycomprehendcausalchainexampleapplicationcarriedClinicalCooperationGroup"PersonalizedRadiotherapyHeadNeckCancer"Helmholtz-ZentrumMünchenLMUMunichdescribedreviewarticlestrivesprovidingcompactoverviewstateartactualchallengesapplicationschanceslimitationsoncologyresearchworkingimprovedpersonalisedconceptsusingrelativelynewmethodology

Similar Articles

Cited By